Zafari J et al., 2024-09-26: Colorectal cancer cell study in which methylene blue photodynamic therapy combined with doxorubicin significantly lowered the doxorubicin IC50 – the closest primary evidence for the 'sensitizes cancer cells to chemotherapy allowing lower doses' half of the claim.
In addition, this mentioned combination led to a considerable decrease in IC50 of DOX. Increased cell membrane lipid peroxidation and cell destruction processes in the combination therapy group
Zafari J et al., 2024-09-26: Colorectal cancer cell study in which methylene blue photodynamic therapy combined with doxorubicin significantly lowered the doxorubicin IC50 – the closest primary evidence for the 'sensitizes cancer cells to chemotherapy allowing lower doses' half of the claim. C7 Zafari 2025. Study type: in vitro cell-line study (HT-29 colorectal adenocarcinoma). Country: Iran. Dose: 'different concentrations' of doxorubicin and methylene blue with a 630 nm low-level diode laser; values not stated in the abstract. Light required: yes for the PDT arm. Funder/conflicts: not stated in the record. Comparator: doxorubicin alone, laser alone, MB alone. Supports the chemosensitisation half only; says nothing about radiation. Study type: lab.
